CYAD.OQ
Latest Trade
10.35USDChange
-0.53(-4.87%)Volume
45,674Today's Range
-
10.8852 Week Range
-
25.36As of on the Euronext Brussels ∙ Minimum 15 minute delay
Previous Close | 10.88 |
|---|---|
Open | 10.59 |
Volume | 45,674 |
3M AVG Volume | 1.89 |
Today's High | 10.88 |
Today's Low | 10.31 |
52 Week High | 25.36 |
52 Week Low | 8.12 |
Shares Out (MIL) | 13.94 |
Market Cap (MIL) | 139.28 |
Forward P/E | -4.38 |
Dividend (Yield %) | -- |
Celyad Says Preliminary Data For Cycle-1 Trial Anticipated During Second Half 2020
Celyad CEO Steps Down, Filippo Petti Nominated For Role
Celyad Receives €8.5 Million Funding By The Walloon Region
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
Industry
Healthcare Facilities
Executive Leadership
Michel E J Lussier
Chairman of the Board, Co-Founder
Filippo J. Petti
Chief Executive Officer, Chief Financial Officer, Director
Gaetane Metz
Chief Operating Officer
Carri Duncan
Vice President Corporate Development and Communications
Anne Moore
Vice President Corporate Strategy
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 233.31 |
Price To Book (MRQ) | 2.92 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 12.06 |
LT Debt To Equity (MRQ) | 8.53 |
Return on Investment (TTM) | -40.77 |
Return on Equity (TTM) | -36.69 |
* GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT
* CELYAD SUCCESSFULLY ADMINISTERS CYAD-01 IN FIRST PATIENTS IN SHRINK AND LINK TRIALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT
* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018
* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL
* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing Source text: [http://bit.ly/2xBg9Sn] Further company coverage:
* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO
* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers
* SHRINK TRIAL IS THIRD CLINICAL TRIAL WITH ITS LEAD PRODUCT CANDIDATE CYAD-01 (CAR-T NKG2D), TARGETING METASTATIC COLORECTAL PATIENTS
* PUBLISHES ADDITIONAL PRE-CLINICAL DATA IN SUPPORT OF THINK TRIAL
* CELYAD OBTAINS ADDITIONAL US PATENT FOR ALLOGENEIC CANCER TREATMENT BASED ON TCR-DEFICIENT CAR-T CELLS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* USE OF CASH OVER Q1 OF 2017 AMOUNTED TO EUR 10.2 MILLION, IN LINE WITH EXPECTATIONS
* FDA GRANTS FAST TRACK DESIGNATION FOR CELYAD’S ISCHEMIC HEART FAILURE THERAPY, C-CURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-Deficient CAR-T Cells Patents
* FY loss of 23.6 million euros versus loss of 29.1 million euros year ago
* The U.S. Patent and Trademark Office (USPTO) rejects new reexamination request against Celyad's US patent for production of allogeneic TCR-deficient CAR-T cells
* Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Celyad registers first hematological patient in CAR-T NKR-2 THINK trial
* Announces registration of first pancreatic cancer patient in its CAR-T NKR-2 THINK Trial in Belgium Source text: http://bit.ly/2jjM82G Further company coverage: (Gdynia Newsroom)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.